Ingalls Kerry D. 4
4 · Poseida Therapeutics, Inc. · Filed Feb 5, 2021
Insider Transaction Report
Form 4
Ingalls Kerry D.
Chief Operating Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2021-02-04+137,000→ 137,000 totalExercise: $9.15Exp: 2031-02-03→ Common Stock (137,000 underlying)
Footnotes (1)
- [F1]12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.